Cytokinetics, Incorporated Faces Class‑Action Over Securities Allegations

On November 11, 2025, law firm DJS Law Group announced a class‑action lawsuit against biotech company Cytokinetics, Incorporated (NASDAQ: CYTK). The suit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b‑5, accusing the company of misleading investors by projecting an FDA approval for its drug candidate aficamten in the second half of 2025, despite failing to submit a required Risk Evaluation and Mitigation Strategy (REMS). The class period is defined as December 27, 2023 to May 6, 2025, with a filing deadline of November 17, 2025 for affected shareholders to join. Participation does not require lead‑plaintiff appointment but allows investors to register and track case progress via portfolio‑monitoring software at no cost or obligation. #Cytokinetics #SecuritiesLitigation #BiotechNews #InvestorRights #SlimScan #GrowthStocks #CANSLIM